[ARCHIVE] Imperial Innovations Group appoints Linda Wilding to the role of Senior Independent Director

– UK – Imperial Innovations Group plc (AIM: IVO) announces that its non-executive director Dr Paul Atherton will not be seeking re-election at the Group’s AGM on 16 December 2014 and will step down from the Board as of that date.

Dr Atherton was appointed to the Board on 29 April 2006, having been a director of the Group’s subsidiary Imperial Innovations Ltd since September 2004.  Dr Atherton currently serves on the Nomination Committee of the Board and previously served on its Remuneration and Audit Committees.

Separately, in accordance with its policy of voluntary compliance with the UK Corporate Governance Code, the Group has appointed non-executive director Linda Wilding to the role of Senior Independent Director with immediate effect.  

Martin Knight, Chairman of Imperial Innovations, said: “On behalf of the Board I would like to thank Paul for his ten years of service, during which he has played an important and influential role in the evolution of the Group.  His experience as a successful scientific entrepreneur and the chairman of technology businesses has ensured that the perspective of founders and managers remains central to our way of doing business.

“In addition to his role on the board of Innovations, Paul co-founded and chaired two of our spin-out companies.  Midaz Lasers was successfully sold to Coherent Inc. in 2012, and Paul continues as the chairman of Nexeon, our largest unquoted investment.

“We look forward to continuing to work together with Paul and thank him for the significant contribution he has made to Innovations over many years.”

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.